The global biopharmaceutical company AbbVie organized a visit to its research centers AbbVie Cambridge Research Center and Worcester Bioresearch Center in Boston, USA, to showcase innovative approaches in drug discovery and development. During the tour, AbbVie's therapeutic areas were presented, providing participants with an overview of the company's leading clinical research and discoveries.
The exclusive session highlighted the CRISP (Clinical Research Advancement Integrated Signature Program), which aims to support the expansion of clinical research in the region, collaborating with the mutual interests of the participating countries in advancing research and establishing a regional research center, helping to improve standards of medical care for patients.
The visit was attended by groups of health leaders, scientists, and other experts from several countries in the region, including Algeria, Saudi Arabia, and the UAE. Participants were introduced to advanced technologies and processes underlying new treatment methods, while experts from these research centers continuously work on innovations, experimenting and pushing the boundaries of medical science.
Experts also participated in valuable discussions focused on science, technology, and leading research in oncology, immunology, and neurology, which advance the company in its mission to unlock and provide innovative medicines and solutions addressing serious health challenges today while also developing medical solutions for the future and improving patients' lives.
Mohammed Abubakr, regional vice-president for the Middle East, Africa, and Russia, stated: "The CRISP (Clinical Research Advancement Integrated Signature Program) program is designed to educate partners on knowledge and skills essential for the advancement and promotion of clinical research in their regions and countries. The project consists of two parts: Experience of research and development platforms and the CRISP Academy.
Additionally, the CRISP Academy was co-established with ACRP (Association of Clinical Research Professionals), aiming to strengthen the commitment of AbbVie to enhance research capabilities and support collaboration in the region." Yasser Nour, regional medical director MEAR AbbVie, added: "From another standpoint, the CRISP program represents a significant scientific project, reinforcing AbbVie's commitment to developing and establishing evidence base. It enhances AbbVie's scientific presence in the regions of the Middle East, Africa, and Russia, significantly impacting patients' lives. Moving forward, we are organizing a clinical research academy to continue enhancing capabilities focusing on foundational research topics."
